טוען...
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...
שמור ב:
| הוצא לאור ב: | Clin Med Insights Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4798019/ https://ncbi.nlm.nih.gov/pubmed/27013902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.Ss34534 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|